MGTX Should I Buy

Piper Sandler raised the firm's price target on MeiraGTx (MGTX) to $30 from $26 and keeps an Overweight rating on the shares following the company's long-term data update in xerostomia and re-acquisition of bota-vec from Johnson & Johnson (JNJ). With the balance sheet bolstered by a concurrent $100M equity raise extending runway into the second half of 2028, Piper continues to like the setup and remains a buyer with a new $30/share target.